DURHAM, N.C., Dec. 18, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Linda M. Richardson as Chief Commercial Officer. Ms. Richardson brings more than 25 years of pharmaceutical sales and marketing experience to Chimerix and will be responsible for establishing the company’s commercial infrastructure and building its capabilities for the potential launch of lead compound brincidofovir. Brincidofovir is currently in a Phase 3 clinical study, SUPPRESS, for the prevention of cytomegalovirus (CMV) in hematopoietic cell transplant recipients (HCT).
Help employers find you! Check out all the jobs and post your resume.
